Thus, Kawasaki et al. explored 46 patients with ESCC who received curative surgery after chemoradiation therapy; 39% of these patients displayed NFE2L2 expression, associated with an unfavorable response to chemoradiation therapy and with lymph node metastases [82]. This evidence concerns the gene NFE2L2 and esophageal squamous cell carcinoma.